AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AstraZeneca’s iCaReMe Global Registry is a real-world multinational study designed to assess the management and quality of care for patients with type 2 diabetes, hypertension, heart failure, and chronic kidney diseases. The study aims to gather comprehensive data on patient characteristics, disease management, healthcare utilization, and outcomes across various countries, providing valuable insights into current clinical practices.
The study does not involve a specific intervention or treatment but rather focuses on collecting observational data through a cloud-based electronic case report form (eCRF). This approach allows for both prospective and retrospective data collection, accessible to participating physicians and the Scientific Committee.
This observational study employs a prospective time perspective and is structured as a patient registry. It does not include specific allocation or intervention models, as its primary purpose is to gather real-world data rather than test a particular treatment.
The study began on February 17, 2018, with an actual start date, and the latest update was submitted on August 11, 2025. These dates highlight the ongoing nature of the registry and its commitment to providing up-to-date information on patient care practices.
The iCaReMe Global Registry could influence AstraZeneca’s stock performance by demonstrating the company’s commitment to improving patient care through data-driven insights. This initiative may also impact investor sentiment positively, as it underscores AstraZeneca’s leadership in addressing chronic health conditions. In the broader industry context, such real-world data collection efforts can set a benchmark for competitors aiming to enhance their own patient management strategies.
The iCaReMe Global Registry is currently recruiting, with further details available on the ClinicalTrials portal.